Norgesic is Absolutely Contraindicated in Glaucoma
Yes, Norgesic (orphenadrine/aspirin/caffeine) is absolutely contraindicated in patients with glaucoma due to the anticholinergic properties of orphenadrine. 1, 2
FDA-Mandated Contraindication
The FDA drug label explicitly states that Norgesic should not be used in patients with glaucoma because of orphenadrine's mild anticholinergic effect. 1 This is a black-and-white contraindication with no exceptions listed in the prescribing information. 2
Mechanism of Risk
Anticholinergic Effects on the Eye
Orphenadrine's anticholinergic properties can precipitate acute angle-closure glaucoma, particularly in individuals predisposed with narrow anterior chamber angles. 3, 4
Anticholinergic medications cause pupillary dilation (mydriasis), which can trigger pupillary block in susceptible patients, leading to acute angle-closure crisis. 3, 4
Most drug-induced glaucoma cases from anticholinergics are of the closed-angle type, which can result in rapid vision loss if not treated emergently. 4
Critical Clinical Distinction
Type of Glaucoma Matters
While the FDA label lists glaucoma as an absolute contraindication without specifying type 1, 2, the clinical reality is more nuanced:
Angle-closure glaucoma (or narrow angles): Anticholinergics pose genuine risk of precipitating acute attacks. 3, 4
Open-angle glaucoma: Anticholinergics are theoretically safer in treated open-angle glaucoma, though the FDA label does not make this distinction. 5
However, given the FDA contraindication and medicolegal implications, Norgesic should be avoided in all glaucoma patients unless absolutely necessary with ophthalmology consultation. 1, 2
Common Prescribing Pitfalls
Real-World Practice Gaps
Many clinicians fail to routinely screen for glaucoma history before prescribing anticholinergics, with studies showing only 49% of urologists routinely inquired about glaucoma before prescribing similar medications. 5
Product inserts mention glaucoma as a contraindication but rarely specify which type, leading to confusion about when the risk is genuine versus theoretical. 3
Potentially inappropriate anticholinergic prescriptions occur in up to 32% of glaucoma patients, often due to inadequate medication reconciliation. 6
Recommended Clinical Approach
Before Prescribing Norgesic
Always ask specifically about glaucoma history before prescribing any medication containing orphenadrine. 5
If glaucoma is present, determine the type: angle-closure versus open-angle, and whether the patient has had laser iridotomy. 5
Consult ophthalmology before proceeding if the patient has any form of glaucoma and Norgesic is being considered. 5
Consider alternative muscle relaxants without anticholinergic properties (such as cyclobenzaprine or methocarbamol) for musculoskeletal conditions. 1
If Patient Develops Visual Symptoms
- Acute angle-closure presents with severe eye pain, headache, blurred vision, halos around lights, and nausea/vomiting - this is an ophthalmologic emergency requiring immediate referral. 3, 4
Bottom Line for Practice
Do not prescribe Norgesic to any patient with glaucoma. The FDA contraindication is clear and unambiguous. 1, 2 The risk of precipitating acute angle-closure glaucoma, particularly in undiagnosed narrow-angle patients, outweighs any potential benefit. 3, 4 Alternative muscle relaxants without anticholinergic properties should be selected instead.